Erythema marginatum hemorrhagicum: A unique cutaneous side effect of sorafenib

Journal of the American Academy of Dermatology

Volumn 64, Issue 6, 2011, Pages 1194-1196

  Rübsam, Katharina ^a   Flaig, Michael J ^a   Ruzicka, Thomas ^a   Prinz, Jörg C ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

SORAFENIB;

ACANTHOSIS; AGED; CASE REPORT; DESQUAMATION; EPIDERMIS; ERYTHEMA; ERYTHEMA MARGINATUM HEMORRHAGICUM; ERYTHROCYTE; HEPATITIS C; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LETTER; LIVER CELL CARCINOMA; LUNG METASTASIS; MALE; METASTASIS; PRIORITY JOURNAL; PRURITUS; SKIN BIOPSY; SKIN PAIN; SKINFOLD; TREATMENT DURATION;

EID: 79956107821     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2009.08.035     Document Type: Article

References (5)

1. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90.
2. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099-109. (Pubitemid 39331023)
3. Robert C, Mateus C, Spatz A, Wechsler J, Escudier B. Dermatologic symptoms associated with the multikinase inhibitor sorafenib. J Am Acad Dermatol 2009;60:299-305.
4. Galán Brotons A, Borrás-Blasco J, Rosique-Robles JD, Vicent Verge JM, Casterá ME. Generalised erythematous skin eruptions induced by sorafenib: cutaneous toxicity and treatment outcome. Clin Transl Oncol 2008;10:844-6.
5. Strumberg D, Awada A, Hirte H, Clark JW, Seeber S, Piccart P, et al. Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: is rash associated with treatment outcome? Eur J Cancer 2006;42:548-56. (Pubitemid 43227936)